Research of Gastric Cancer Therapeutics in Asia-Pacific : Share, Trends and Application 2017

ALBANY, NY, FEB 28, 2017 : Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach and is the fifth-most common cancer globally. There are many types of gastric cancer, but adenocarcinoma is the most common type and is diagnosed in 95% of cases. The life expectancy and survival rate for gastric cancer is heavily dependent on the stage of the disease when diagnosed. In Asia-Pacific, most of the incident cases of gastric cancer are diagnosed at the late stage and in patients over the age of 60. As the aged population continues to grow, the prevalence of gastric cancer will increase. This, coupled with increasing early diagnosis and an improved survival rate, will drive revenue growth. Due to its indolent nature, the disease remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved targeted therapeutic options. The current marketed products landscape comprises a wide range of treatment options, including HER2-targeted therapy, angiogenesis inhibitors and new chemotherapies. Nevertheless, significant unmet need remains for products that can treat HER2-negative gastric cancer patients. However, the gastric cancer market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on targeted therapies.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=840987

In the current market, patients with HER2-positive gastric cancer can be treated with targeted therapies, such as Herceptin, while HER2-negative patients still receive chemotherapy regimens as the first-line treatment. The market will be driven by recently launched products and upcoming targeted therapies during the forecast period. The main restraints will be the low penetration of new targeted therapies, owing to their high price, and constrained healthcare budgets.

Scope

The Asia-Pacific gastric cancer market is forecast to grow at a compound annual growth rate of 11.4% from $1.3 billion in 2015 to $2.7 billion in 2022.

How will angiogenesis inhibitors contribute to growth?
What effect will the patent expirations of branded therapies have on market value?

The pipeline contains a range of molecule types and molecular targets, including those that are well-established in gastric cancer and novel targeted therapies.

Which molecular targets appear most frequently in the pipeline?
Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
What are the most promising first-in-class targets for gastric cancer?
Will the current first-in-class targets have broader therapeutic potential across the Asia-Pacific markets?
Will the pipeline address unmet needs such as a lack of targeted treatments for HER2-negative gastric cancer patients?

Various drivers and barriers will influence the market over the forecast period.

What are the barriers that limit the uptake of premium-priced targeted therapeutics in the assessed countries?
Which factors are most likely to drive the market in these countries?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=840987

Licensing deals are the most common form of strategic alliance in gastric cancer, with total deal values ranging from under $10m to over $200m.

How do deal frequency and value compare between target families and molecule types?
What were the terms and conditions of key licensing deals?

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
90 State Street,
Albany, NY 12207,
United States

This release was published on openPR.